miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway

miR-34a 和 miR-125a-5p 通过抑制 MACC1 介导的 PI3K/AKT/mTOR 通路抑制肝细胞癌细胞增殖和转移,但诱导细胞凋亡

阅读:7
作者:Y M Zhang, Q M Wu, L Y Chang, J C Liu

Abstract

microRNA-34a (miR-34a) and microRNA-1251-5p (miR-125a-5p) were considered as tumor suppressors in hepatocellular carcinoma (HCC). Nevertheless, the modulatory mechanisms of miR-34a and miR-125a-5p in HCC haven't been completely understood. The levels of metastasis-associated with colon cancer 1 (MACC1) and miRNAs (miR-34a and miR-125a-5p) were determined by quantitative real-time polymerase chain reaction (qRT-PCR), and the levels of associated proteins were detected by western blot assay. Cell proliferation and metastasis were examined via Cell Counting Kit-8 (CCK-8) and transwell assays, respectively. Cell apoptosis was measured through flow cytometry. The effect of MACC1 on HCC in vivo was explored via xenograft assay. Dual-luciferase reporter assay and RNA Immunoprecipitation (RIP) assay were implemented to explore the target correlation. The expression of MACC1 was upregulated in HCC tissues and cells. Knockdown of MACC1 inhibited proliferation and metastasis but expedited apoptosis of HCC cells and the repression of tumor growth in vivo was evoked by MACC1 downregulation. Both miR-34a and miR-125a-5p directly targeted MACC1 and repressed the expression of MACC1 in HCC cells. Overexpression of miR-34a or miR-125a-5p restrained cell proliferation and metastasis while induced apoptosis by downregulating MACC1 in HCC cells. miR-34a and miR-125a-5p repressed phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signal pathway via reducing MACC1 in HCC cells. miR-34a and miR-125a-5p refrained proliferation and metastasis while motivated apoptosis in HCC cells through the PI3K/AKT/mTOR pathway by repressing MACC1. miR-34a and miR-125a-5p might be splendid biomarkers in the therapeutic strategies for HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。